Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Total 13F shares
-
34,651,491
-
Share change
-
+1,329,430
-
Total reported value
-
$2,474,382,581
-
Price per share
-
$71.55
-
Number of holders
-
51
-
Value change
-
+$136,089,518
-
Number of buys
-
37
-
Number of sells
-
25
Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q4 2020
As of 31 Dec 2020,
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,651,491 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, FMR LLC, HILLHOUSE CAPITAL ADVISORS, LTD., VANGUARD GROUP INC, BlackRock Inc., UBS ASSET MANAGEMENT AMERICAS INC, PRICE T ROWE ASSOCIATES INC /MD/, Rock Springs Capital Management LP, and MASSACHUSETTS FINANCIAL SERVICES CO /MA/.
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.